Vertaling van "years and older " (Nederlands → Frans) :

Ilaris (ACZ885, canakinumab) (USD 6 million) is a biologic medicine approved in more than 40 countries to treat adults and children aged four years and older suffering from cryopyrin-associated periodic syndrome (CAPS), a group of rare auto-inflammatory disorders that affect approximately one in one million people.
Ilaris (ACZ885, canakinumab) (USD 6 millions), est un médicament biologique autorisé dans plus de quarante pays pour traiter les adultes et les enfants de plus de quatre ans souffrant du syndrome périodique associé à la cryopirine (CAPS), un groupe de maladies auto-inflammatoires qui touche environ une personne sur un million.

The CHMP gave a positive opinion for the approval of tobramycin inhalation powder (TOBI Podhaler) for the suppressive therapy of chronic pulmonary infection due to Pseudomonas aeruginosa in adult and children age six years and older with cystic fibrosis.
inhalation (TOBI Podhaler) pour le traitement suppressif de l’infection pulmonaire chronique due au pseudomonas aeruginosa chez les adultes et les enfants de plus de six ans atteints de fibrose cystique.

Ilaris (ACZ885) (USD 6 million), is the first medicine to treat adults and children aged four years and older suffering cryopyrin-associated periodic syndrome (CAPS), a group of rare autoinflammatory disorders that affect one in one million people.
Ilaris (ACZ885) (USD 6 million), est le premier médicament pour traiter les adultes et les enfants de plus de quatre ans souffrant du syndrome périodique associé à la cryopirine (CAPS), un groupe de maladies auto-inflammatoires qui touche une personne sur un million.

Bespreking van: Bejan-Angoulvant T, Saadatian-Elahi M, Wright J et al. Treatment of hypertension in patients 80 years and older : the lower the better ?
Analyse de: Bejan-Angoulvant T, Saadatian-Elahi M, Wright J et al. Treatment of hypertension in patients 80 years and older : the lower the better ?

BMJ 2011; 342:d2040. Lewis JR, Calver J, Zhu K, et al. Calcium supplementation and the risks of atherosclerotic vascular disease in older women: results of a 5-year RCT and a 4.5 year follow-up.
Heart 2012; 98:920-5. van der Sijs IH, Ho-Dac-Pannekeet MM. The treatment of hypomagnesemia.

1A).7, 8 shows the danger of combined risk factors, as these tend to interact: all three for stroke important risk factors give you the stroke risk of a person that is not less than 32 years older.
7, 8 Figure 2 shows the danger of combined risk factors, as these tend to interact: all three for stroke important risk factors give you the stroke risk of a person that is not less than 32 years older.